Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
FL Thanks for the clarification. Very interesting, as always. I am wondering, can you quantify the impact on sales of the market introduction of Septicyte RAPID in Europe? How important is it, is this one of the killer apps you have long been talking about? BL
BL As far as I can tell there are probably at least 10 rapid point of care SARs-COV-2 test systems on the market with EUA's in the US. I'm less certain about the status of the EU approvals. The tests fall into two categories viral antigen (quick but less accurate) and nucleic acid/PCR (take longer but more accurate). Idylla will never be a high volume system but I think it could fill the following two niche markets: 1) As a pre-surgical precaution to protect medical staff. Currently most colonoscopy, breast lumpectomy, lung phlebotomy, etc procedures are asking patients to get a COVID test 48 to 72 hours prior to the procedure. This takes the chance that the patient does not become infected after the testing but before the procedure. I can see a case for using Idylla in a hospital setting before letting the patient into the room where the procedures are conducted. I don't know that a lot of new consoles would be sold for this purpose but it seemingly be a welcome offering for physicians that are already using Idylla in a POC environment. The number of cartridges used for each of these existing units could easily triple or quadruple under this scenario. 2) the second application is the one we have discussed already. Use of the COVID test in combination with Septicyte Rapid in an Emergency Room setting for triaging patients. I think this is a large market but is dependent on the validation demonstration. In the EU, it is already available. Hopefully, some of the users will author studies on the use of Septicyte Rapid that increase the traction of the test. Some of the very limited data presented during the ImmunExpress SCCM presentation suggested that the test could provide a early indication of patients likely to have an immune response likely to develop into sepsis. Assuming the validation shows considerable utility then the product will have a strong market. My guess is that during a normal year adoption traction would probably be slow, maybe a hundred additional consoles sold per year with maybe a 20% growth rate as practitioners share their experiences. During a pandemic these rates could be greatly accelerated as ER's look for ways to more efficiently utilize resources. Immunexpress showed a slide during one of their presentations that suggested that the more accurate diagnosis of ER patients likely to develop sepsis could potentially save several thousand dollars of cost per patient over a typical (if there is a typical) COVID hospitalization. As such, the payback to the hospital could be very rapid. If the validation study works out or a landmark user paper/positive large hospital study release then the combination Septicyte/COVID test could unlock a large market with accelerating sales. Under this scenario, I could see a couple hundred additional console sales in the next year (this assumes that some of the larger partners JnJ etc. co-promote Idylla use). Because these would be POC rather than RUO applications I would think the cartridge utilization rates would be much higher than anything we have seen previously (say 700 to 1500 tests per year per console). So under this scenario, maybe we see roughly a doubling of the cartridge sales. God willing, the COVID market should dissipate in the 2nd half of 2021 as the percentage of the population vaccinated increases toward the herd immunity levels. After that the growth trajectory would probably look like a more typical year. Probably not the Killer App unless the market persists at accelerated rates for several years. I'm hopeful this does not become the case! I still think the use of EGFR assays in Asian countries with high incidence of the mutation and limited placement of NGS has the makings of a great market assuming a strong partner like AZN co-promotes Idylla. The question marks are when will Idylla be approved for full IVD use and what will the reimbursement rates be? ESMO and other conferences are emphasizing faster TAT of MDx data for NSCLC treatment. Some of the papers are emphasizing that this MDx data is key to decision making during the COVID pandemic. Fast TAT MDx data is integral determining whether the patient should be treated via chemo, oral drug regimes, etc. Idylla is well situated for this niche market. EGFR and the Fusion panel is more likely a killer Ap in my mind. Once again, a lot of conjecture. FL
Ivel schreef op 3 september 2020 14:05 :
[...]
Kan je mij 1 biotechbedrijf noemen die niet veel cashburn heeft?
Ontplooiing van dergelijke medische apparatuur en bijbehoren duurt jaren eer het winstgevend wordt.
Pharming group (AMX) :)
Resem nieuwe vacatures nl. Operatoren voor 2 ploegen systeem(plus vrijwillig op zaterdag). Lab operations Manager. Head of Risk and Complience. Er wordt daar niet stilgezeten in Mechelen. Vooral de gezochte operatoren voor 2ploegenstelsel en zaterdagwerk geeft mij een hoopgevend gevoel.
Flatlander schreef op 22 september 2020 17:30 :
BL
... the combination Septicyte/COVID test could unlock a large market with accelerating sales. Under this scenario, I could see a couple hundred additional console sales in the next year (this assumes that some of the larger partners JnJ etc. co-promote Idylla use). Because these would be POC rather than RUO applications I would think the cartridge utilization rates would be much higher than anything we have seen previously (say 700 to 1500 tests per year per console). So under this scenario, maybe we see roughly a doubling of the cartridge sales ...
FL
FL Bcart is clearly expecting a lot from the Septicyte/COVID test. Attached is a table with the quarterly cartridge sales data which I compiled recently. The quarterly numbers are not provided by Bcart, but if you go back long enough through the quarterly updates and half and full year financial reports, you can extrapolate the exact numbers. There are a number of key take-aways: 1. up until the end of 2018 there was a nice sequential quarterly (high) growth rate in the numbers, 2. we can clearly point the finger at the Fisher and COVID19 problems (in red) for the slowing of sales, but once Covid is resolved, there is no reason why high sequential growth cannot resume in the (near?) future, and even with Covid... 3. Bcart is clearly expecting a lot from the Septicyte/COVID test as can be seen in the numbers (Q4'20). Verrelst said in the conference call that he expects this year only a 12% YonY quarterly growth from the base (oncology) business. So in order to get to a projected yearly total of 228.000, no less than 32.000 Covid cartridges will have to be sold in Q4 alone. Of course, Verrelst may have his reasons for underestimating base business and overestimating the Covid test sales, 4. assuming sequential growth will resume, or assuming the Q4 sales number will just carry on into next year (as projected in the table), with the Covid test picking up the slack until the base business resumes its normal growth path, Bcart may well be back on track for decent growth. At first glance the Covid test sales number seems unusually high, so maybe there is a mistake in my numbers, but I don't see it. Anyway, I find the information sufficiently interesting for it to be shared. BL
BL I believe 393,000 cartridges in 2021 is achievable given the new product mix that will be introduced. Oncology MDx demand is anticipated to be at an all time high next year as the pandemic delayed procedures result in more serious disease. I see EGFR gaining a lot of traction in 2021. It will be a bit of a sales challenge with the combined infectious disease and oncology focus, That is why I think the initial sales of the COVID test will be in the settlings where Idylla is already deployed. The geographic access to the higher reimbursement rate markets (US, Japan, UAE, etc) will be critical in moving the needle toward cash flow positive. Regards FL
Ilumina Acquisition of Grail is perplexing. Illumina sells NGS sequencing equipment to a variety of labs and content developers (Guardant, Archer & many others). Why would they buy a content provider (primarily liquid biopsy)? Will this move drive more content developers to migrate where possible to an alternate platform such as Fisher Scientific NGS equipment? While Illumina has had a long history with Grail, my guess is that Illumina got serious about the acquisition road when Fisher was going to acquire Qiagen. I can't help asking whether this acquisition will trigger additional consolidation of NGS providers? The industry is growing fast an is extremely fragmented. One of the things that initially attracted me to BCART is that they control their Idylla platform and can build out their own content as well as partner sponsored content. Grail is taking direct aim at EXAS precision oncology unit (formerly GHDX plus a few other additions). I believe EXAS would be well served by differentiating from Grail's offerings (when they hit the market) by moving into the point of care environment by launching OncoType on Idylla. If they do not proceed that way they will likely find themselves one of many lab based MDx tests. The TailorX study advantage will likely dissipate with time as other assays become more accurate. FL
PERSBERICHT: Persbericht Biocartis Group NV: Resultaten van de buitengewone algemene aandeelhoudersvergadering gehouden op 25 september 2020 FONDS KOERS VERSCHIL VERSCHIL % BEURS Biocartis NV 4,50 -0,05 -1,10 % Euronext Brussel PERSBERICHT: GEREGLEMENTEERDE INFORMATIE 25 september 2020, 17:40 CEST Resultaten van de buitengewone algemene aandeelhoudersvergadering gehouden op 25 september 2020 Mechelen, België, 25 september 2020 -- Biocartis Group NV (de 'Vennootschap' of 'Biocartis'), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), hield vandaag zijn buitengewone algemene aandeelhoudersvergadering. De aandeelhouders keurden alle punten op de agenda van de buitengewone algemene aandeelhoudersvergadering goed. Alle documenten betreffende de aandeelhoudersvergadering kunnen geraadpleegd worden op de website www.globenewswire.com/Tracker?data=U1... van de Vennootschap. --- EINDE --- Meer informatie: Renate Degrave Hoofd Corporate Communications & Investor Relations Biocartis e-mail www.globenewswire.com/Tracker?data=cP... rdegrave@biocartis.com tel +32 15 631 729 gsm +32 471 53 60 64
You'll have to excuse me. In 25 years of investing in Nasdaq and NYSE listed companies I've never seen a similar Share Premium Capital redistribution. They did not post the material in English, here is the translation of some of the pertinent parts I found in the meeting materials release. So if my read is right, is this share premium adjustment done to 1) reduce 2019 tax liability? Did Belgium extend 2019 tax due dates appreciably due to Coronavirus? and 2) Set the 2020 financials on better footing? Anyone want to explain or hypothesize on the reasoning. "please refer to the summons to the extraordinary general shareholders' meeting. EXTRAORDINARY GENERAL MEETING Agenda and proposals to conclude: The agenda and proposals to conclude the Extraordinary General Shareholders' Meeting of the Company, which may, where appropriate, be amended at the meeting on behalf of the Board of Directors are as follows: 1. Capital increase by incorporation of issuance premiums followed by capital reduction to discharge losses Notes: This item on the agenda concerns the proposal that the extraordinary general shareholders' meeting decides to increase the Company's capital without issuing new and equity by incorporating part of the issue premium, and to reduce the company's capital immediately after the aforementioned capital increase in accordance with Article 7:210 of the Code of Companies and Associations through the incorporation of losses incurred as shown by the single financial statements for the financial year ended December 31, 2019. Proposal to conclude The General Meeting decides to increase (i) the Company's capital by a sum of one hundred and four million seventy thousand five hundred and ninety-five cents (€ 104,070.59 4.45) without issuance of new shares and by incorporation of part of the issue premium (as shown by the single financial statements for the financial year ended December 31, 2019) in the Company's capital , and (ii) to reduce the company's capital immediately after the aforementioned capital increase in accordance with Article 7:210 of the Code of Companies and Associations with an amount of one hundred and four million seventy thousand five hundred and ninety-four cents (€ 104.07 0.594.45) to bring it back to five hundred and sixty-three thousand eight hundred and eighty-eight cents Extraordinary General Shareholders' Meeting of 25 September 2020 Page 2 Notes (€ 563,820.88) , by means of the inclusion of losses for the previous amount of one hundred and four million seventy thousand five hundred and ninety-five cents forty-five cents (€ 104,070,594.45), as shown by the single annual accounts for the financial year ended 31 December 2019. The aforementioned capital reduction (i) will first be allocated to all amounts that do not qualify as tax-filled (or equivalent) capital, (ii) will take place without the destruction of the Company's existing shares, and (iii) will be borne by each of the Company's existing shares in the same manner. 2. Submitting the Executive Board's special report pursuant to Article 7:199 of the Code of Companies and Associations on the proposal to renew the authorised capital Explanatory Note: This item on the agenda concerns the presentation, knowledge and discussion of the Governing Council's special report in accordance with Article 7:199 of the Code of Companies and Associations on the proposal to renew the powers granted to the Governing Council under the authorized capital. A copy of this document is available on the Company's website and at the Company's headquarters."
Hennie76 schreef op 27 september 2020 09:13 :
vimeo.com/460354197/cec0521ebd Een groot compliment voor cfo Jean Marc Roelandt voor deze duidelijke kwaliteitsvolle uiteenzetting. Dit geeft een mens vertouwen.
Flatlander schreef op 26 september 2020 18:39 :
You'll have to excuse me. In 25 years of investing in Nasdaq and NYSE listed companies I've never seen a similar Share Premium Capital redistribution. They did not post the material in English, here is the translation of some of the pertinent parts I found in the meeting materials release. So if my read is right, is this share premium adjustment done to 1) reduce 2019 tax liability? Did Belgium extend 2019 tax due dates appreciably due to Coronavirus? and 2) Set the 2020 financials on better footing? Anyone want to explain or hypothesize on the reasoning.
"please refer to the summons to the extraordinary general shareholders' meeting. EXTRAORDINARY GENERAL MEETING Agenda and proposals to conclude: The agenda and proposals to conclude the Extraordinary General Shareholders' Meeting of the Company, which may, where appropriate, be amended at the meeting on behalf of the Board of Directors are as follows: 1. Capital increase by incorporation of issuance premiums followed by capital reduction to discharge losses Notes: This item on the agenda concerns the proposal that the extraordinary general shareholders' meeting decides to increase the Company's capital without issuing new and equity by incorporating part of the issue premium, and to reduce the company's capital immediately after the aforementioned capital increase in accordance with Article 7:210 of the Code of Companies and Associations through the incorporation of losses incurred as shown by the single financial statements for the financial year ended December 31, 2019. Proposal to conclude The General Meeting decides to increase (i) the Company's capital by a sum of one hundred and four million seventy thousand five hundred and ninety-five cents (€ 104,070.59 4.45) without issuance of new shares and by incorporation of part of the issue premium (as shown by the single financial statements for the financial year ended December 31, 2019) in the Company's capital , and (ii) to reduce the company's capital immediately after the aforementioned capital increase in accordance with Article 7:210 of the Code of Companies and Associations with an amount of one hundred and four million seventy thousand five hundred and ninety-four cents (€ 104.07 0.594.45) to bring it back to five hundred and sixty-three thousand eight hundred and eighty-eight cents Extraordinary General Shareholders' Meeting of 25 September 2020 Page 2 Notes (€ 563,820.88) , by means of the inclusion of losses for the previous amount of one hundred and four million seventy thousand five hundred and ninety-five cents forty-five cents (€ 104,070,594.45), as shown by the single annual accounts for the financial year ended 31 December 2019. The aforementioned capital reduction (i) will first be allocated to all amounts that do not qualify as tax-filled (or equivalent) capital, (ii) will take place without the destruction of the Company's existing shares, and (iii) will be borne by each of the Company's existing shares in the same manner. 2. Submitting the Executive Board's special report pursuant to Article 7:199 of the Code of Companies and Associations on the proposal to renew the authorised capital Explanatory Note: This item on the agenda concerns the presentation, knowledge and discussion of the Governing Council's special report in accordance with Article 7:199 of the Code of Companies and Associations on the proposal to renew the powers granted to the Governing Council under the authorized capital. A copy of this document is available on the Company's website and at the Company's headquarters."
I asked myself and the rest of this site the same question when this shareholder meeting was made public and no one seems to know. Looks like they found someone/something to pour in fresh 'starter' capital and then immediately erase it with the debt. Which would serve nicely to clean up their balance sheet and no more interest/monthly costs dragging down their financial numbers. Someone in Biocartis has deep pockets.
@Flatlander: bedankt voor de tip van een tijdje terug, gisteren ingestapt.
Novacyt is a great contrast to BCART they are small nimble and innovative. They get product to the market very quickly. It has made up for my BCART losses. I have thought that they should buy BCART and use their technology to greatly accelerate Idylla offerings. I now see that the BCART presentations are estimating China and Japan registrations at the end of 2021. The Amgen US registration filing is delayed due to COVID. The EUA's for COVID are even taken longer than I expected. I still maintain that BCART could be a great long term holding if they can access the POC market. They are apparently doing this with some assays in the EU, South America and Canada. If the Webinar I posted a few weeks ago is right, COVID will be a catalyst to move MDx to the POC environment (or at least out of centralized labs). So I'm on the hook for another year looking for the long awaited inflection point! FL
GoedeDag I was disappointed that the meeting materials were only released in Dutch, The google document translate took a long time and totally lost all formatting. One 28 page paragraph. I lost patience and did not make it all the way thru the document. I must admit that there are provisions in the Belgium market that I do not totally understand. I have done well with MDx investments. BCART is my sole loser, thus far. I constantly look for evidence that I might be missing something. Thus far, other than some delayed projects I've yet to find conclusive evidence that the POC cancer MDx thesis is wrong. While NGS turnaround time was coming down before COVID, Idylla still had a nice TAT advantage and a cost advantage. I think the most likely competition is smaller cheaper NGS units placed closer to the patient. This battle is ongoing and Idylla could use more content to drive adoption. I guess we need to look toward the 3rd Qtr update/capital markets day in November fot updates on these fronts.. FL
Flatlander schreef op 29 september 2020 15:33 :
GoedeDag
I was disappointed that the meeting materials were only released in Dutch, The google document translate took a long time and totally lost all formatting. One 28 page paragraph. I lost patience and did not make it all the way thru the document. I must admit that there are provisions in the Belgium market that I do not totally understand.
I have done well with MDx investments. BCART is my sole loser, thus far. I constantly look for evidence that I might be missing something. Thus far, other than some delayed projects I've yet to find conclusive evidence that the POC cancer MDx thesis is wrong. While NGS turnaround time was coming down before COVID, Idylla still had a nice TAT advantage and a cost advantage. I think the most likely competition is smaller cheaper NGS units placed closer to the patient. This battle is ongoing and Idylla could use more content to drive adoption.
I guess we need to look toward the 3rd Qtr update/capital markets day in November fot updates on these fronts..
FL
Gisteren gekocht en voormiddag verkocht, goede zaak gedaan, goede raad is goud waard, BC blijft zeker in mijn portefeuille zitten, groeten.
I trimmed a little on the 25% runup this morning but I'm still holding the majority of my position. They are minting cash, eliminated all debt and are building a nice war chest. Their Primer Design group is very agile. FL
Hi FL, @ what price did you step in? Today's closing 5,67€
Voor de mensen die klant zijn bij Bolero. Beste klant, U bent van harte uitgenodigd voor een exclusief online event op zaterdag 10 oktober om 10 uur. Naar goede gewoonte zetten we met KBC Securities de biotechsector in de kijker, deze keer in een volledig digitale editie! KBC Securities-analisten Sandra Cauwenberghs en Lenny Van Steenhuyse trappen de livestream af met een sectoroverzicht. Gevolgd door bedrijfspresentaties van Herman Verrelst, CEO Biocartis, Stijn Van Rompay, CEO Hyloris en Piet Wigerinck, CSO Galapagos. Elke presentatie wordt gevolgd door een Q&A-sessie. Het ideale moment om uw vraag direct te stellen aan het aanwezige management! Mis dit unieke event niet: De livestream gaat door van 10u tot 12u30 op zaterdag 10 oktober Inschrijven is gratis, maar wel verplicht Het volledige programma vindt u op de inschrijvingspagina. Phoene
Bought in on ALNOV on July 13 at 2.80. The price tanked that day on a great earnings report. I remember buying in thinking that people are selling the news way too early since the pandemic and COVID testing were only in the initial stages. That said, Novacyt had already run a fair amount before I bought in, so I'm sure the seller thought it was time to bank their gain. Either way I'm playing with the houses money now! FL
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee